GET DAILY SIGNALSFractyl Health (GUTS) Stock Plunges -82% in 30 Days: Clinical Data and Restructuring in Focus
Key Takeaways
- Fractyl Health (GUTS) shares fell roughly 82% over the past 30 days, declining from about $4.41 to around $0.81 at the latest close.
- The slide accelerated after the company reported six-month data from its REMAIN-1 study, alongside a newly filed securities class-action lawsuit, triggering a single-session decline of about 63%.
- A subsequent restructuring—including a roughly 45% workforce reduction and the discontinuation of the Rejuva gene therapy program—further pressured investor sentiment.
- Over the last quarter the stock has dropped roughly 90%, extending a longer multi-month downtrend for the clinical-stage metabolic therapeutics company.
- Shares now trade below $1.00, bringing Nasdaq minimum bid-price requirements into focus as a key risk investors are monitoring.
- Analyst consensus remains constructive on the name, but the near-term story hinges on the upcoming quarterly report and progress toward an FDA submission for Revita.
Company Background for Fractyl Health (GUTS)
Fractyl Health, Inc. is a clinical-stage metabolic therapeutics company headquartered in Burlington, Massachusetts. The company is developing therapies intended to treat type 2 diabetes (T2D) and obesity by addressing the organ-level root causes of metabolic disease rather than managing symptoms alone. Its lead product candidate, the Revita DMR System, is an outpatient procedural therapy designed to modify duodenal dysfunction, a condition associated with high-fat and high-sugar diets that can initiate T2D and obesity. Fractyl is positioning Revita as a potential durable, one-time procedural option for post-GLP-1 weight maintenance. The company has also developed Rejuva, an adeno-associated virus-delivered pancreatic gene therapy platform, though it has since announced plans to discontinue internal development of that program. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance for GUTS
GUTS has experienced an exceptionally sharp decline over both short- and medium-term horizons. Over the last 30 days, the stock fell approximately 82%, from a closing level near $4.41 to roughly $0.81. The most dramatic move occurred in a single trading session in mid-October, when the shares tumbled about 63% in one day following the company's REMAIN-1 data readout and a concurrent class-action lawsuit filing. The quarterly picture is even steeper. Measured against a closing level near $8.42 about three months earlier, the stock has lost roughly 90% of its value. This prolonged slide reflects a combination of clinical-readout disappointment, legal uncertainty, a corporate restructuring, and a broader repricing of a pre-revenue biotechnology company trading below the $1.00 threshold.
Drivers Behind the Recent Decline
The dominant catalyst behind the recent move was the release of six-month results from the REMAIN-1 study of the Revita DMR System. The company reported that the study met its pre-specified six-month co-primary endpoint of weight-loss retention, with patients treated with a single Revita procedure showing greater weight maintenance after stopping GLP-1 therapy compared with the sham group. Despite these positive signals, the shares fell sharply, as a securities class-action lawsuit was filed the same session alleging that the company made false or misleading statements regarding the Revita DMR System study. The downturn was compounded by subsequent corporate announcements. Fractyl disclosed a workforce reduction of approximately 45% and stated it would discontinue internal development of the Rejuva gene therapy program while seeking strategic alternatives for the asset. The company said the moves concentrate its financial and operational resources on advancing Revita toward a potential FDA marketing application, and that its cash runway extends into the second quarter of 2027. The company also announced it had strengthened its Revita patent portfolio ahead of a planned submission. From what I see, this combination of events shifted sentiment quickly.
Quarterly Trends and Broader Context
The quarterly decline reflects a steady erosion of investor confidence that began well before the October selloff. Through the late summer and early autumn, the stock drifted lower from the $8–$9 range amid uncertainty around the timing and interpretation of the pivotal REMAIN-1 readout. Second-quarter 2026 results, reported in August, highlighted a net loss and limited cash runway, reinforcing the pre-revenue, capital-intensive nature of the business even as management pointed to positive clinical signals and reiterated key milestones. The October events—the data readout, the lawsuit, and the restructuring—converted that gradual decline into an accelerated repricing. The discontinuation of Rejuva removed a secondary value driver from the narrative, leaving Revita's regulatory and commercial prospects as the central determinant of the company's outlook. I’m watching this closely as the situation develops.
Looking Ahead: Key Factors to Monitor
Several factors are likely to shape Fractyl Health's stock in the near term. First, the company's third-quarter 2026 financial results and business update are scheduled for mid-November, with investors watching for updates on cash position, the restructuring, and the Revita regulatory timeline. Second, the planned De Novo marketing application submission for Revita—previously targeted for late in the fourth quarter—remains a pivotal milestone for the company's commercial path. Third, the stock's position below $1.00 introduces Nasdaq minimum bid-price compliance considerations, which the company may need to address if the shares remain under that threshold for a sustained period. Fourth, the outcome and progression of the securities class-action lawsuit could influence sentiment. Finally, broader biotechnology-sector conditions, funding appetite, and competitive developments in the GLP-1 and weight-management space will continue to affect how investors value a pre-revenue metabolic therapeutics company. These are risk factors to monitor rather than a basis for any investment decision. In my view, the upcoming earnings will provide important clarity.
AI Tools in My Research Process
In my research, I've found Tickeron's Trending AI Robots page helpful for spotting data-driven trading ideas across various strategies and timeframes. It offers a focused selection of top-performing automated bots that trade thousands of tickers, allowing for comparisons of different systematic approaches without committing to any single recommendation. This has been a useful resource when evaluating names like GUTS amid volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GUTS in -12.81% downward trend, sliding for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GUTS declined for three days, in 160 of 173 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for GUTS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for GUTS just turned positive on November 02, 2026. Looking at past instances where GUTS's MACD turned positive, the stock continued to rise in 17 of 21 cases over the following month. The odds of a continued upward trend are 81%.
Following a +12.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where GUTS advanced for three days, in 105 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
GUTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GUTS's P/B Ratio (-88.892) is slightly lower than the industry average of (3.498). P/E Ratio (-1.022) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. GUTS's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. GUTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GUTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement